Mucin quantity on MRI and outcomes following total neoadjuvant therapy in patients with rectal cancer Journal Article

  


Authors: Javed-Tayyab, S.; Miranda, J.; de Paula, T. R.; Nevin, R.; Pinto, P. V. A.; Zheng, J. T.; Firat, C.; El Homsi, M.; Rodriguez, L.; Capanu, M.; Weiser, M. R.; Shia, J.; Gollub, M. J.; Horvat, N.
Article Title: Mucin quantity on MRI and outcomes following total neoadjuvant therapy in patients with rectal cancer
Abstract: Objectives To evaluate the relationship between mucin quantity on MRI and outcomes following total neoadjuvant therapy (TNT) in patients with rectal cancer. Materials and methods This retrospective, single-center study included patients with rectal adenocarcinoma who underwent TNT followed by surgery or non-operative management (NOM) from January 2018-December 2019. Two abdominal radiologists independently scored baseline and restaging MRIs for mucin quantity in the tumor or tumor bed, using two classifications: < 50% vs. >= 50% (similar to histological classification) and no mucin vs. any mucin. Statistical analysis was performed to determine if patient outcomes differed between tumors of different mucin quantities. Results Among 189 patients, 114/189 (60%) male, 75/189 (40%) female), the median age at diagnosis was 57 years (IQR: 48-68). On baseline MRI, 29/189 (15%) patients had tumor containing any amount of mucin, and on restaging MRI, 27/189 (14%) patients had tumor containing any mucin. 103/189 (54%) underwent surgery after TNT, and 86/189 (46%) underwent NOM. 59/189 (31%) experienced local recurrence, distant recurrence, or local regrowth. There were no significant differences in the rate of pathologic complete response/sustained clinical complete response, time to local recurrence/local regrowth, time to distant recurrence, and disease-free survival between tumors of different mucin quantity, regardless of the timing and criteria for determining mucin quantity (< 50% vs. >= 50% mucin criteria, and no vs. any mucin criteria on baseline MRI, restaging MRI and on histopathology, respectively). Conclusion Mucin on restaging MRI should not rule out NOM or prompt more aggressive therapy in the absence of other high-risk features.
Keywords: neoadjuvant therapy; magnetic resonance imaging; adenocarcinoma; carcinoma; rectal neoplasms; colon; mucinous; subtype; colorectum
Journal Title: European Radiology
ISSN: 0938-7994
Publisher: Springer  
Publication status: Online ahead of print
Date Published: 2025-01-01
Online Publication Date: 2025-01-01
Language: English
ACCESSION: WOS:001559403200001
DOI: 10.1007/s00330-025-11967-6
PROVIDER: wos
Notes: Article; Early Access -- Source: Wos
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
Related MSK Work